ArticleTranslational pediatrics2026
Pegaspargase-associated cerebral venous sinus thrombosis: risk factors and anticoagulation management in pediatric acute lymphoblastic leukemia-a case series.
Article in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite improving outcomes in pediatric acute lymphoblastic leukemia (ALL), pegaspargase (PEG-ASP) carries a risk of cerebral venous sinus thrombosis (CVST), for which optimal anticoagulation management in children remains undefined. This retrospective case series aimed to analyze the incidence, associated factors, and management outcomes of PEG-ASP-associated CVST in pediatric ALL patients. Among 741 ALL patients treated at a single center over a 3-year period, the incidence of PEG-ASP-associated CVST was 1.4% (11 cases). Case Description: Eleven pediatric ALL patients who developed PEG-ASP-associated CVST were stratified by disease severity [intensive care unit (ICU) admission Conclusions: The study highlights a significant association between cumulative PEG-ASP dose and CVST severity in this pediatric ALL cohort. The findings support the feasibility and safety of extended anticoagulation therapy alongside continued chemotherapy, without interrupting PEG-ASP treatment, leading to favorable clinical and neurological outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.